Pharmaceutical products | Tenderlake

Pharmaceutical products

Contract Value:
EUR 1 - 1
Notice Type:
Contract Notice
Published Date:
20 January 2023
Closing Date:
01 March 2023
Location(s):
DEA51 Bochum, Kreisfreie Stadt (DE Germany/DEUTSCHLAND)
Description:
Drug discount agreements according to § 130a Abs. 8 SGB V 2023-1

The invitation to tender serves to conclude agreements with pharmaceutical companies within the meaning of section 130a (8) of the Social Code (SGB) Fifth Book (V) (hereinafter: discount agreements or discount agreement) with

a duration of 24 calendar months for prescription drugs and pharmacy-only medicines that do not require a prescription. According to § 130a (8) sentence 1 SGB V, the invitation to tender is only available to pharmaceutical entrepreneurs or

Bidding consortia of pharmaceutical companies within the meaning of § 4 (18) of the German Medicines Act (AMG). It is already made clear that for lots 001 to 075 framework agreements with three tenderers, for lots 076 to 098 framework agreements with two tenderers and

for lots 099 to 123, framework agreements may be concluded with a tenderer.

In this case, a consortium is considered to be one bidder. Further details can be found in the tender documents.

Active ingredient: acetylsalicylic acid, Type of prescription: pharmacy, Dosage form: KTA, TAB, TMR, GRA in bag, ATC code: B01AC06

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Active ingredient: candesartan and hydrochlorothiazide, Prescription type: prescription, Dosage form: TAB, ATC code: C09DA06

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Active ingredient: colecalciferol, Prescription type: prescription, Dosage form: WKA, ATC code: A11CC05

Framework agreements are concluded with an economic operator for lots 099 to 123.

Wirkstoff: Darunavir, Verschreibungsart: verschreibungspflichtig, Darreichungsform: FTA, ATC-Code: J05AE10

Framework agreements are concluded with an economic operator for lots 099 to 123.

Active ingredient: diclofenac, type of prescription: prescription, dosage form: SUP, ATC code: M01AB05

Framework agreements are concluded with an economic operator for lots 099 to 123.

Active ingredient: estriol, Prescription type: prescription, Dosage form: OVU, ATC code: G03CA04

Framework agreements are concluded with an economic operator for lots 099 to 123.

Active ingredient: formoterol, Prescription: prescription, Dosage form: IHP, ATC code: R03AC13

Framework agreements are concluded with an economic operator for lots 099 to 123.

Active ingredient: Glatiramer, Prescription: prescription, Dosage form: FER, ATC code: L03AX13

Framework agreements are concluded with an economic operator for lots 099 to 123.

Active ingredient: glibenclamide, Prescription type: prescription, Dosage form: TAB, ATC code: A10BB01

Framework agreements are concluded with an economic operator for lots 099 to 123.

Active ingredient: ibandronic acid, Type of prescription: prescription, Dosage form: FTA, ATC code: M05BA06

Framework agreements are concluded with an economic operator for lots 099 to 123.

Active ingredient: ibandronic acid, type of prescription: prescription, dosage form: IFK, ATC code: M05BA06

Framework agreements are concluded with an economic operator for lots 099 to 123.

Active ingredient: isosorbide mononitrate, type of prescription: prescription, dosage form: RED, REK, RET, ATC code: C01DA14

Framework agreements are concluded with an economic operator for lots 099 to 123.

Active ingredient: carvedilol, Prescription: prescription, Dosage form: FTA, TAB, ATC code: C07AG02

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Active ingredient: isosorbide mononitrate, type of prescription: prescription, dosage form: TAB, ATC code: C01DA14

Framework agreements are concluded with an economic operator for lots 099 to 123.

Active ingredient: lamivudine, Prescription type: prescription, Dosage form: FTA, ATC code: J05AF05

Framework agreements are concluded with an economic operator for lots 099 to 123.

Active ingredient: lanreotide, type of prescription: prescription, dosage form: ILO, ATC code: H01CB03

Framework agreements are concluded with an economic operator for lots 099 to 123.

Active ingredient: mesalazine, Type of prescription: prescription, Dosage form: RGR in sachet, RGR in sachet msr., RET, ATC code: A07EC02

Framework agreements are concluded with an economic operator for lots 099 to 123.

Active ingredient: mometasone, Prescription type: prescription, Dosage form: CRE, ATC code: D07AC13

Framework agreements are concluded with an economic operator for lots 099 to 123.

Active ingredient: mometasone, Prescription type: prescription, Dosage form: LOE, ATC code: D07AC13

Framework agreements are concluded with an economic operator for lots 099 to 123.

Active ingredient: mometasone, Prescription type: prescription, Dosage form: SAL, ATC code: D07AC13

Framework agreements are concluded with an economic operator for lots 099 to 123.

Active ingredient: morphine, Prescription type: prescription, Dosage form: FTA, HKP, ATC code: N02AA01

Framework agreements are concluded with an economic operator for lots 099 to 123.

Active ingredient: ofloxacin, prescription type: prescription, dosage form: AUS, ATC code: S01AE01

Framework agreements are concluded with an economic operator for lots 099 to 123.

Active ingredient: propafenone, Prescription type: prescription, Dosage form: FTA, TAB, UTA, ATC code: C01BC03

Framework agreements are concluded with an economic operator for lots 099 to 123.

Active ingredient: chlormadinone and ethinyl estradiol, type of prescription: prescription, dosage form: FTA, ATC code: G03AA15

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Active ingredient: Rupatadin, Prescription: prescription, Dosage form: TAB, ATC code: R06AX28

Framework agreements are concluded with an economic operator for lots 099 to 123.

Active ingredient: Salbutamol, Prescription type: prescription, Dosage form: LOV - solution for inhalation, ATC code: R03AC02

Framework agreements are concluded with an economic operator for lots 099 to 123.

Active ingredient: Triamcinolone acetonide, Prescription type: prescription, Dosage form: CRE, ATC code: D07AB09

Framework agreements are concluded with an economic operator for lots 099 to 123.

Active ingredient: venlafaxine, Prescription type: prescription, Dosage form: FTA, TAB, ATC code: N06AX16

Framework agreements are concluded with an economic operator for lots 099 to 123.

Active ingredient: ciprofloxacin, prescription type: prescription, dosage form: FTA, ATC code: J01MA02

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Active ingredient: citalopram, type of prescription: prescription, dosage form: FTA, ATC code: N06AB04

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Active ingredient: clopidogrel, Prescription type: prescription, Dosage form: FTA, ATC code: B01AC04

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Wirkstoff: Diclofenac, Verschreibungsart: verschreibungspflichtig, Darreichungsform: BTA, FTA, HKP, HKM, TMR, PSE, TSE, UTA, WKA, ATC-Code: M01AB05

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Active ingredient: diclofenac, prescription type: prescription, dosage form: RED, REC, REK fast, SL-REC, RET, RET fast, ATC code: M01AB05

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Active ingredient: dienogest and ethinyl estradiol, type of prescription: prescription, dosage form: FTA, TAB, UTA, ATC code: G03AA16

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Active ingredient: Enalapril, Prescription type: prescription, Dosage form: TAB, ATC code: C09AA02

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Wirkstoff: Alendronsäure, Verschreibungsart: verschreibungspflichtig, Darreichungsform: BTA, FTA, TAB, ATC-Code: M05BA04

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Wirkstoff: Entecavir, Verschreibungsart: verschreibungspflichtig, Darreichungsform: FTA, ATC-Code: J05AF10

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Wirkstoff: Erlotinib, Verschreibungsart: verschreibungspflichtig, Darreichungsform: FTA, ATC-Code: L01EB02

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Active ingredient: ezetimibe, prescription type: prescription, dosage form: TAB, ATC code: C10AX09

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Active ingredient: ezetimibe and simvastatin, type of prescription: prescription, dosage form: TAB, ATC code: C10BA02

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Wirkstoff: Febuxostat, Verschreibungsart: verschreibungspflichtig, Darreichungsform: FTA, ATC-Code: M04AA03

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Active ingredient: fentanyl, Prescription: prescription, Dosage form: PFT, ATC code: N02AB03

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Active ingredient: formoterol, Prescription type: prescription, Dosage form: HPI, ATC code: R03AC13

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Active ingredient: furosemide, type of prescription: prescription, dosage form: TAB, ATC code: C03CA01

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Active ingredient: gabapentin, type of prescription: prescription, dosage form: FTA, HKP, ATC code: N03AX12

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Active ingredient: glimepiride, Prescription type: prescription, Dosage form: TAB, ATC code: A10BB12

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Wirkstoff: Allopurinol, Verschreibungsart: verschreibungspflichtig, Darreichungsform: FTA, TAB, UTA, ATC-Code: M04AA01

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Active ingredient: Hydrochlorothiazide, Prescription type: prescription, Dosage form: TAB, ATC code: C03AA03

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Active ingredient: ibandronic acid, Prescription: prescription, Dosage form: ILO, ATC code: M05BA06

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first- and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer for that lot will be discounted and awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid ultimately follows in the 2-partner model.

Wirkstoff: Ibuprofen, Verschreibungsart: verschreibungspflichtig, Darreichungsform: FTA, KTA, TAB, KAP, UTA, SMT, Weichgelatinekapseln, ATC-Code: M01AE01

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Active ingredient: ibuprofen, Prescription type: pharmacy only, Dosage form: SUE, SIR, ATC code: M01AE01

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Wirkstoff: Lisinopril, Verschreibungsart: verschreibungspflichtig, Darreichungsform: FTA, TAB, ATC-Code: C09AA03

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Wirkstoff: Losartan, Verschreibungsart: verschreibungspflichtig, Darreichungsform: FTA, ATC-Code: C09CA01

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first- and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer for that lot will be discounted and awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid ultimately follows in the 2-partner model.

Active ingredient: losartan and hydrochlorothiazide, type of prescription: prescription, dosage form: FTA, ATC code: C09DA01

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Wirkstoff: Memantin, Verschreibungsart: verschreibungspflichtig, Darreichungsform: FTA, SMT, ATC-Code: N06DX01

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Active ingredient: mesalazine, Prescription type: prescription, Dosage form: SUP, ATC code: A07EC02

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Active ingredient: mesalazine, type of prescription: prescription, dosage form: TMR, ATC code: A07EC02

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Active ingredient: ambrisentan, type of prescription: prescription, dosage form: FTA, ATC code: C02KX02

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Active ingredient: metamizole, type of prescription: prescription, dosage form: FTA, TAB, ATC code: N02BB02

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Active substance: metamizole, Prescription: prescription, Dosage form: LSE, TEI, LOE, ATC code: N02BB02

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Active ingredient: metformin, Prescription type: prescription, Dosage form: FTA, TAB, ATC code: A10BA02

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Active ingredient: Metoprolol succinate, Prescription type: prescription, Dosage form: RET, ATC code: C07AB02

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Wirkstoff: Metoprolol tartrat, Verschreibungsart: verschreibungspflichtig, Darreichungsform: FTA, LTA, TAB, ATC-Code: C07AB02

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Active ingredient: Metoprolol tartrate, Prescription type: prescription, Dosage form: RET, ATC code: C07AB02

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Active ingredient: mirtazapine, Prescription type: prescription, Dosage form: FTA, SMT, ATC code: N06AX11

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Wirkstoff: Montelukast, Verschreibungsart: verschreibungspflichtig, Darreichungsform: FTA, TAB, ATC-Code: R03DC03

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Active ingredient: morphine, Prescription type: prescription, Dosage form: REK, RET, Application frequency 2 x daily, ATC code: N02AA01

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Active ingredient: moxonidine, Prescription type: prescription, Dosage form: FTA, ATC code: C02AC05

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Active ingredient: amlodipine, type of prescription: prescription, dosage form: TAB, ATC code: C08CA01

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Wirkstoff: Mycophenolat mofetil, Verschreibungsart: verschreibungspflichtig, Darreichungsform: FTA, HKP, TAB, ATC-Code: L04AA06

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first- and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer for that lot will be discounted and awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid ultimately follows in the 2-partner model.

Active ingredient: ofloxacin, Prescription type: prescription, Dosage form: ATR, ATC code: S01AE01

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Active ingredient: omeprazole, Prescription type: prescription, Dosage form: HKM, KAP, KMR, MRP in KAP, TMR, ATC code: A02BC01

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Active substance: oxycodone, Prescription type: prescription, Dosage form: FTA, HKP, ATC code: N02AA05

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Active ingredient: oxycodone, Prescription type: prescription, Dosage form: RET, ATC code: N02AA05

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Active ingredient: pantoprazole, Prescription type: prescription, Dosage form: TMR, ATC code: A02BC02

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first- and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer for that lot will be discounted and awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid ultimately follows in the 2-partner model.

Wirkstoff: Pravastatin, Verschreibungsart: verschreibungspflichtig, Darreichungsform: FTA, TAB, ATC-Code: C10AA03

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Active ingredient: Prednisolone, Prescription type: prescription, Dosage form: TAB, ATC code: H02AB06

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Active ingredient: propiverine, Prescription type: prescription, Dosage form: FTA, UTA, ATC code: G04BD06

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Active ingredient: quetiapine, type of prescription: prescription, dosage form: RET, ATC code: N05AH04

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Active ingredient: amoxicillin, Prescription type: prescription, Dosage form: FTA, TAB, Oblong tablets, ATC code: J01CA04

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Active ingredient: ramipril, Prescription type: prescription, Dosage form: FTA, HKP, KAP, TAB, ATC code: C09AA05

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Active ingredient: ramipril and hydrochlorothiazide, type of prescription: prescription, dosage form: FTA, TAB, ATC code: C09BA05

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Wirkstoff: Risperidon, Verschreibungsart: verschreibungspflichtig, Darreichungsform: FTA, SMT, SMF, ATC-Code: N05AX08

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Wirkstoff: Rosuvastatin, Verschreibungsart: verschreibungspflichtig, Darreichungsform: FTA, ATC-Code: C10AA07

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Active ingredient: simvastatin, Prescription type: prescription, Dosage form: FTA, ATC code: C10AA01

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Wirkstoff: Sitagliptin, Verschreibungsart: verschreibungspflichtig, Darreichungsform: FTA, ATC-Code: A10BH01

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Active ingredient: sitagliptin and metformin, type of prescription: prescription, dosage form: FTA, ATC code: A10BD07

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Active ingredient: tamsulosin, Prescription type: prescription, Dosage form: RET, ICP retaded, HVW, ATC code: G04CA02

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Active ingredient: Topiramate, Prescription type: prescription, Dosage form: FTA, HKP, ATC code: N03AX11

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first- and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer for that lot will be discounted and awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid ultimately follows in the 2-partner model.

Active ingredient: Torasemide, Prescription: prescription, Dosage form: TAB, ATC code: C03CA04

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Active ingredient: bicalutamide, Prescription type: prescription, Dosage form: FTA, ATC code: L02BB03

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Active ingredient: tramadol, type of prescription: prescription, dosage form: FTA, HKP, TAB, ATC code: N02AX02

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Active ingredient: tramadol, prescription type: prescription, dosage form: HKP retarded, RET (application 2 x daily), ATC code: N02AX02

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Active ingredient: tramadol, type of prescription: prescription, dosage form: LSE, TEI, LOE, ATC code: N02AX02

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Active ingredient: venlafaxine, Type of prescription: prescription, Dosage form: HKP retarded, RET, ATC code: N06AX16

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Active ingredient: zoledronic acid, Prescription: prescription, Dosage form: INF, ATC code: M05BA08

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Active ingredient: zonisamide, Prescription type: prescription, Dosage form: HKP, ATC code: N03AX15

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Active substance: Artovastatin and ezetimibe, Prescription type: prescription, Dosage form: FTA, HKP, TAB, ATC code: C10BA05

Framework agreements are concluded with 2 economic operators for lots 076 to 098.

If, for the lots in the 2-partner model, the difference in savings between the potentially eligible first- and second-placed offers of a lot is greater than 40%, then the respective second-placed offer with regard to this lot falls out of the evaluation and the

The contract is ultimately awarded in the 1-partner model.

Active ingredient: bisoprolol and hydrochlorothiazide, Prescription type: prescription, Dosage form: FTA, TAB, ATC code: C07BB07

Framework agreements are concluded with 2 economic operators for lots 076 to 098.

If, for the lots in the 2-partner model, the difference in savings between the potentially eligible first- and second-placed offers of a lot is greater than 40%, then the respective second-placed offer with regard to this lot falls out of the evaluation and the

The contract is ultimately awarded in the 1-partner model.

Active ingredient: cinacalcet, type of prescription: prescription, dosage form: FTA, ATC code: H05BX01

Framework agreements are concluded with 2 economic operators for lots 076 to 098.

If, for the lots in the 2-partner model, the difference in savings between the potentially eligible first- and second-placed offers of a lot is greater than 40%, then the respective second-placed offer with regard to this lot falls out of the evaluation and the

The contract is ultimately awarded in the 1-partner model.

Active ingredient: colecalciferol, type of prescription: pharmacy, dosage form: TAB, ATC code: A11CC05

Framework agreements are concluded with 2 economic operators for lots 076 to 098.

If, for the lots in the 2-partner model, the difference in savings between the potentially eligible first- and second-placed offers of a lot is greater than 40%, then the respective second-placed offer with regard to this lot falls out of the evaluation and the

The contract is ultimately awarded in the 1-partner model.

Wirkstoff: Bisoprolol, Verschreibungsart: verschreibungspflichtig, Darreichungsform: FTA, LTA, TAB, ATC-Code: C07AB07

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Active ingredient: Dimethyl fumarate, Prescription type: prescription, Dosage form: HKM, ATC code: L04AX07

Framework agreements are concluded with 2 economic operators for lots 076 to 098.

If, for the lots in the 2-partner model, the difference in savings between the potentially eligible first- and second-placed offers of a lot is greater than 40%, then the respective second-placed offer with regard to this lot falls out of the evaluation and the

The contract is ultimately awarded in the 1-partner model.

Active ingredient: dronedarone, type of prescription: prescription, dosage form: FTA, ATC code: C01BD07

Framework agreements are concluded with 2 economic operators for lots 076 to 098.

If, for the lots in the 2-partner model, the difference in savings between the potentially eligible first- and second-placed offers of a lot is greater than 40%, then the respective second-placed offer with regard to this lot falls out of the evaluation and the

The contract is ultimately awarded in the 1-partner model.

Active ingredient: enalapril and hydrochlorothiazide, type of prescription: prescription, dosage form: TAB, ATC code: C09BA02

Framework agreements are concluded with 2 economic operators for lots 076 to 098.

If, for the lots in the 2-partner model, the difference in savings between the potentially eligible first- and second-placed offers of a lot is greater than 40%, then the respective second-placed offer with regard to this lot falls out of the evaluation and the

The contract is ultimately awarded in the 1-partner model.

Active ingredient: latanoprost and timolol, type of prescription: prescription, dosage form: ATR, ATC code: S01ED51

Framework agreements are concluded with 2 economic operators for lots 076 to 098.

If, for the lots in the 2-partner model, the difference in savings between the potentially eligible first- and second-placed offers of a lot is greater than 40%, then the respective second-placed offer with regard to this lot falls out of the evaluation and the

The contract is ultimately awarded in the 1-partner model.

Active ingredient: levodopa and carbidopa, type of prescription: prescription, dosage form: RET, ATC code: N04BA02

Framework agreements are concluded with 2 economic operators for lots 076 to 098.

If, for the lots in the 2-partner model, the difference in savings between the potentially eligible first- and second-placed offers of a lot is greater than 40%, then the respective second-placed offer with regard to this lot falls out of the evaluation and the

The contract is ultimately awarded in the 1-partner model.

Active ingredient: levodopa and carbidopa, prescription type: prescription, dosage form: TAB, ATC code: N04BA02

Framework agreements are concluded with 2 economic operators for lots 076 to 098.

If, for the lots in the 2-partner model, the difference in savings between the potentially eligible first- and second-placed offers of a lot is greater than 40%, then the respective second-placed offer with regard to this lot falls out of the evaluation and the

The contract is ultimately awarded in the 1-partner model.

Active ingredient: levonorgestrel and ethinyl estradiol, type of prescription: prescription, dosage form: FTA, ATC code: G03AA07

Framework agreements are concluded with 2 economic operators for lots 076 to 098.

If, for the lots in the 2-partner model, the difference in savings between the potentially eligible first- and second-placed offers of a lot is greater than 40%, then the respective second-placed offer with regard to this lot falls out of the evaluation and the

The contract is ultimately awarded in the 1-partner model.

Active ingredient: levonorgestrel and ethinyl estradiol, type of prescription: prescription, dosage form: UTA, ATC code: G03AA07

Framework agreements are concluded with 2 economic operators for lots 076 to 098.

If, for the lots in the 2-partner model, the difference in savings between the potentially eligible first- and second-placed offers of a lot is greater than 40%, then the respective second-placed offer with regard to this lot falls out of the evaluation and the

The contract is ultimately awarded in the 1-partner model.

Active ingredient: mesalazine, Prescription: prescription, Dosage form: RSC, ATC code: A07EC02

Framework agreements are concluded with 2 economic operators for lots 076 to 098.

If, for the lots in the 2-partner model, the difference in savings between the potentially eligible first- and second-placed offers of a lot is greater than 40%, then the respective second-placed offer with regard to this lot falls out of the evaluation and the

The contract is ultimately awarded in the 1-partner model.

Active ingredient: metoclopramide, Prescription type: prescription, Dosage form: FTA, KAP, TAB, ATC code: A03FA01

Framework agreements are concluded with 2 economic operators for lots 076 to 098.

If, for the lots in the 2-partner model, the difference in savings between the potentially eligible first- and second-placed offers of a lot is greater than 40%, then the respective second-placed offer with regard to this lot falls out of the evaluation and the

The contract is ultimately awarded in the 1-partner model.

Active ingredient: candesartan, Prescription type: prescription, Dosage form: TAB, ATC code: C09CA06

Framework agreements are concluded with 3 economic operators for lots 001 to 075.

If the difference in savings between the potential first-place and second-placed offers of a lot for the lots in the 3-partner model is greater than 40%, then the respective second and third placed offer with respect to that lot will fall out of the classification and the bid will ultimately be awarded in the 1-partner model.

If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.

Active ingredient: morphine, Type of prescription: prescription, Dosage form: ILO, ATC code: N02AA01

Framework agreements are concluded with 2 economic operators for lots 076 to 098.

If, for the lots in the 2-partner model, the difference in savings between the potentially eligible first- and second-placed offers of a lot is greater than 40%, then the respective second-placed offer with regard to this lot falls out of the evaluation and the

The contract is ultimately awarded in the 1-partner model.

Active ingredient: ofloxacin, Prescription type: prescription, Dosage form: ATR (single-dose pipettes), ATC code: S01AE01

Framework agreements are concluded with 2 economic operators for lots 076 to 098.

If, for the lots in the 2-partner model, the difference in savings between the potentially eligible first- and second-placed offers of a lot is greater than 40%, then the respective second-placed offer with regard to this lot falls out of the evaluation and the

The contract is ultimately awarded in the 1-partner model.

Active ingredient: raloxifene, Prescription type: prescription, Dosage form: FTA, ATC code: G03XC01

Framework agreements are concluded with 2 economic operators for lots 076 to 098.

If, for the lots in the 2-partner model, the difference in savings between the potentially eligible first- and second-placed offers of a lot is greater than 40%, then the respective second-placed offer with regard to this lot falls out of the evaluation and the

The contract is ultimately awarded in the 1-partner model.

Active substance: rosuvastatin and ezetimibe, type of prescription: prescription, dosage form: FTA, TAB, ATC code: C10BA06

Framework agreements are concluded with 2 economic operators for lots 076 to 098.

If, for the lots in the 2-partner model, the difference in savings between the potentially eligible first- and second-placed offers of a lot is greater than 40%, then the respective second-placed offer with regard to this lot falls out of the evaluation and the

The contract is ultimately awarded in the 1-partner model.

Active ingredient: salbutamol, type of prescription: prescription, dosage form: DOS, ATC code: R03AC02

Framework agreements are concluded with 2 economic operators for lots 076 to 098.

If, for the lots in the 2-partner model, the difference in savings between the potentially eligible first- and second-placed offers of a lot is greater than 40%, then the respective second-placed offer with regard to this lot falls out of the evaluation and the

The contract is ultimately awarded in the 1-partner model.

Active ingredient: Salbutamol, Prescription type: prescription, Dosage form: LOV - Ready inhalate, ATC code: R03AC02

Framework agreements are concluded with 2 economic operators for lots 076 to 098.

If, for the lots in the 2-partner model, the difference in savings between the potentially eligible first- and second-placed offers of a lot is greater than 40%, then the respective second-placed offer with regard to this lot falls out of the evaluation and the

The contract is ultimately awarded in the 1-partner model.

Wirkstoff: Verapamil, Verschreibungsart: verschreibungspflichtig, Darreichungsform: FTA, LTA, UTA, ATC-Code: C08DA01

Framework agreements are concluded with 2 economic operators for lots 076 to 098.

If, for the lots in the 2-partner model, the difference in savings between the potentially eligible first- and second-placed offers of a lot is greater than 40%, then the respective second-placed offer with regard to this lot falls out of the evaluation and the

The contract is ultimately awarded in the 1-partner model.

Active ingredient: verapamil, type of prescription: prescription, dosage form: REC, RET, ATC code: C08DA01

Framework agreements are concluded with 2 economic operators for lots 076 to 098.

If, for the lots in the 2-partner model, the difference in savings between the potentially eligible first- and second-placed offers of a lot is greater than 40%, then the respective second-placed offer with regard to this lot falls out of the evaluation and the

The contract is ultimately awarded in the 1-partner model.

Wirkstoff: Zolmitriptan, Verschreibungsart: verschreibungspflichtig, Darreichungsform: FTA, SMT, TAB, ATC-Code: N02CC03

Framework agreements are concluded with 2 economic operators for lots 076 to 098.

If, for the lots in the 2-partner model, the difference in savings between the potentially eligible first- and second-placed offers of a lot is greater than 40%, then the respective second-placed offer with regard to this lot falls out of the evaluation and the

The contract is ultimately awarded in the 1-partner model.

Active ingredient: colecalciferol, Prescription type: prescription, Dosage form: TEI, ATC code: A11CC05

Framework agreements are concluded with an economic operator for lots 099 to 123.

Download full details as .pdf
The Buyer:
Deutsche Rentenversicherung Knappschaft-Bahn-See (KBS)
CPV Code(s):
33600000 - Pharmaceutical products